Ligand Pharmaceuticals Incorporated (LGND)
- Previous Close
69.89 - Open
69.46 - Bid 70.42 x 100
- Ask 71.25 x 100
- Day's Range
69.17 - 71.00 - 52 Week Range
49.24 - 94.57 - Volume
152,955 - Avg. Volume
174,309 - Market Cap (intraday)
1.257B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
23.43 - EPS (TTM)
3.03 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 2, 2010
- 1y Target Est
116.80
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
www.ligand.comRecent News: LGND
Performance Overview: LGND
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LGND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LGND
Valuation Measures
Market Cap
1.26B
Enterprise Value
1.09B
Trailing P/E
23.43
Forward P/E
26.53
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.60
Price/Book (mrq)
1.79
Enterprise Value/Revenue
8.32
Enterprise Value/EBITDA
10.93
Financial Highlights
Profitability and Income Statement
Profit Margin
39.72%
Return on Assets (ttm)
0.79%
Return on Equity (ttm)
8.29%
Revenue (ttm)
131.31M
Net Income Avi to Common (ttm)
53.82M
Diluted EPS (ttm)
3.03
Balance Sheet and Cash Flow
Total Cash (mrq)
170.31M
Total Debt/Equity (mrq)
0.88%
Levered Free Cash Flow (ttm)
-4.76M
Research Analysis: LGND
Company Insights: LGND
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: LGND
LGND: Lowering target price to $73.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLGND: Lowering target price to $84.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLGND: Raising target price to $86.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLGND: Raising target price to $77.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $77.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target